Abstract 188: Cost of control for achieving glycemic treatment targets in adults with Type 2 diabetes treated with insulin degludec/insulin aspartin a real-world Indian setting: A post-hoc analysis of ARISE study

Aim: To evaluate the cost of control of insulin degludec/insulin aspart (IDegAsp) in people with T2DM from ARISE study as compared to previous therapy (OADs ± previous insulins ± GLP-1 RAs) based on Indian setting. Methods: ARISE was a ~26 weeks open-label, non-interventional study (NCT04042441) including 1102 T2DM adults on any anti-hyperglycaemic treatment initiating or switching to IDegAsp based on investigator's discretion as per local practice in 6 countries, with 185 patients from India. For this post-hoc analysis, a short-term cost of control model developed in Microsoft Excel was used to estimate the difference in yearly cost of control for IDegAsp versus other therapies from a patient payer perspective. Data from ARISE study was used with regards to the baseline cohort characteristics, treatment effects and for the proportion of patients achieving treatment targets. Drug acquisition costs based on maximum retail price in India as of October 2022 were taken into consideration, and the healthcare resource utilization costs were derived from other published literature. Results: When assessing the Indian cohort, IDegAsp was associated with lower annual cost of control than all treatments towards achieving HbA1c <7% (by ₹ 9,86,738), and HbA1c less than pre-defined individual treatment target (by ₹ 16,75,108). The difference in yearly total costs including that of medication and healthcare resource use was lower with IDegAsp as compared to all treatment (by ₹ 2955.83). The number needed to treat to bring one patient to targets of HbA1c <7.0% and less than pre-defined individual treatment target was lower with IDegAsp than continuation of all baseline treatment options, 11.24 vs 23.26 & 10.53 vs 31.25, respectively. Conclusion: Under Indian setting, IDegAsp was shown to be a cost-effective treatment for people with type 2 diabetes not achieving glycemic targets on other therapies in routine clinical practice.